Fig. 7.

Intracisternal administration of anti-PAI-1 antibody abolish EAE relapses of PLP-induced EAE mice. a Clinical score evolution, b survival curves, c peak disease severity, d cumulative score, e incidence of mice with NSS ≥ 3 and f incidence of relapse for PLP-induced EAE animals treated with control antibody (n = 9) or anti-PAI-1 antibody (MA-MP6H6; n = 19). Antibodies were administered in the cisterna magna at the day of EAE onset. g Representative immunostaining of PAI-1 in the high thoracic spinal cord from PLP-induced EAE animals treated with control antibody or anti-PAI-1 antibody at acute (16 dpi), remission (28 dpi) and late stages (45 dpi) during PLP-induced EAE (DAPI: blue) and h the PAI-1 positive area quantification in the total spinal cord as percentage of white matter area (n = 3). Data are represented as mean ± SEM and analyzed with a Two-way ANOVA followed by FDR test, b, e, f log-rank (Mantel–Cox) test and c, d, h Mann–Whitney U test *p < 0.05; **p < 0.01, ***p < 0.001. Scale bars: 20 µm